In a subsequent phase III trial, the TeloVac study, GV1001 with GM-CSF adjuvant, failed to show an improvement in OS when added to chemotherapy alone in patients with advanced pancreatic cancer. Here, CSF2 is linked to familial pancreatic carcinoma.